真空辅助切除术在减少导管异型性过度治疗中的作用
回顾性分析2009年4月至2016年3月连续乳腺筛查患者中初次诊断性空心针活检为AIDEP/ADH或FEA的B3病变273例,评估真空辅助切除术(VAE)联合钼靶监测替代手术的安全性。187/273(68.5%)仅行VAE后5年钼靶监测,34/273(12.5%)VAE诊断恶性,51/273(19%)在新路径下诊断癌症,17/273(6.2%)在5年监测期间发生恶性。结论认为VAE是管理导管异型性的安全手术替代方案。
要点
- 初次空心针活检为AIDEP/ADH或FEA的B3病变中,68.5%(187/273)仅行VAE即可避免手术。
- VAE可术前诊断66.7%(34/51)的癌症,使患者接受单次治疗性手术。
- 5年钼靶监测期间6.2%(17/273)发生恶性,其中12例浸润性癌均HER2阴性。
核心结论
- VAE是管理导管异型性(AIDEP/ADH和FEA)的安全手术替代方案,68.5%(187/273)女性避免手术,66.7%(34/51)癌症经VAE术前诊断而接受单次治疗性手术。
研究设计与样本
- 回顾性分析前瞻性收集的数据,纳入2009年4月至2016年3月连续乳腺筛查患者中初次诊断性空心针活检为AIDEP/ADH或FEA的B3病变273例,随访至2019年4月(5年监测期)。
诊断标准与关键数值
- 187/273(68.5%)仅行VAE无恶性升级后接受5年钼靶监测。
- 34/273(12.5%)经VAE诊断恶性。
- 24/273(8.8%)因影像或病理关注行VAE后手术活检,其中8/24升级为恶性。
- 22/273(8%)行手术诊断性活检,其中9/22(41%)升级为恶性。
- 共51/273(19%)在新路径下诊断癌症:13例浸润性(均ER阳性、Her2阴性)和38例非浸润性(34例DCIS、4例LCIS)。
临床应用与阅片要点
- 对初次活检为AIDEP/ADH或FEA的B3病变,可考虑VAE联合钼靶监测作为手术替代方案(作者提出)。
- 5年监测期间17/273(6.2%)发生恶性:12例浸润性(均HER2阴性)、4例DCIS和1例LCIS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: B3 lesions are indeterminate lesions of uncertain malignant potential. They include lesions with and without epithelial atypia. Those with atypia include atypical intraductal epithelial proliferation (AIDEP)/atypical ductal hyperplasia (ADH) and flat epithelial atypia (FEA). They are traditionally managed with surgery. Vacuum assisted excision (VAE) allows larger samples to be obtained using a vacuum assisted biopsy (VAB) device, which equates to a surgical biopsy. We propose that VAE and mammographic surveillance is a safe alternative to surgery in managing the ductal atypias; (AIDEP/ADH and FEA).
METHOD: Retrospective analysis of prospectively collected data on B3 lesions (April 2009 - March 2016) from consecutive breast screening patients diagnosed with AIDEP/ADH or FEA on initial diagnostic core biopsy. Mammographic abnormality, breast density, size, management pathway and upgrade to cancer and types of cancer were also collected during the treatment pathway and 5 year surveillance period (April 2009 - April 2019).
RESULTS: 273 cases of ductal atypia were identified. 187/273 (68.5 %) cases were managed with VAE only as no upgrade to malignancy and then 5 year mammographic surveillance. 34/273 (12.5 %) cases had a VAE diagnosing malignancy. 24/273 (8.8 %) cases had a VAE and then a surgical biopsy due to radiological or pathological concern, 8/24 upgraded to malignancy. 22/273 (8%) cases had a surgical diagnostic biopsy, 9/22 (41 %) cases were upgraded to malignancy. In total 51/273 (19 %) cases were diagnosed with cancer on the new pathway (13 invasive (all ER positive and Her2 negative) and 38 non-invasive, (34 ductal carcinoma in situ (DCIS) and 4 cases of lobular carcinoma in situ (LCIS)). While 17/273 (6.2 %) cases developed malignancy (12 invasive (all HER2 negative) and 4 DCIS and 1 LCIS) during the 5 year surveillance period.
CONCLUSIONS: VAE is a safe alternative to surgery in managing ductal atypias. 187/273 (68.5 %) women avoided surgery. While 34/51 cancers (66.7 %) were diagnosed preoperatively using VAE, allowing the women to have a single therapeutic procedure.
引用
- McMahon MA, Haigh I, Chen Y, et al. Role of vacuum assisted excision in minimising overtreatment of ductal atypias. Eur J Radiol. 2020. PMID: 32919262. doi:10.1016/j.ejrad.2020.109258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。